Abstract
The use of corifollitropin alfa (CA) in assisted reproductive technology (ART) cycles is
dependent on the antral follicle count and body weight of patients. The present study investigated the safety and efficacy of using 100μg of CA in predicted excessive responders based
on serum anti-Mullerian hormone (AMH) level. The results of 381 ART cycles stimulated by
CA versus daily recombinant follicle-stimulation hormone (rFSH) in patients with low (<1.0
ng/mL; n = 38 vs. n = 90), moderate (1.0–3.36 ng/mL; n = 38 vs. n = 95), and high (> 3.36
ng/mL; n = 48 vs. n = 72) serum AMH levels, were analyzed. Pregnancy and live birth rates
did not significantly differ between CA and daily rFSH groups. In the patients with high AMH
levels, serum progesterone (P4) levels on the day of human chorionic gonadotropin (hCG)
injection were significantly lower in the CA group than in the rFSH group (0.93 ± 0.55 vs.
1.16 ± 0.64 ng/mL). Furthermore, serum P4 levels on the day of hCG injection were negatively correlated with baseline AMH levels in the CA group, but not in the rFSH group, in the
patients with high AMH levels. In conclusion, the use of 100 μg of CA in patients with high
AMH levels is safe and effective and is associated with a lower P4 level on the day of hCG
injection compared with the use of daily rFSH.
